eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
3/2008
vol. 4
 
Share:
Share:
more
 
 

Clinical research
Prohepcidin and its possible role in anaemia of pregnancy

Leszek Rams
,
Lena Drozdowska-Rams
,
Jacek Małyszko
,
Krystyna Pawlak
,
Jolanta Małyszko

Arch Med Sci 2008; 4, 3: 305–309
Online publish date: 2008/10/15
Article file
- Prohepcidin.pdf  [0.06 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction
Normal pregnancy is characterized by profound changes in almost every organ system to accommodate the demands of the fetoplacental unit. A greater increase in intravascular volume compared to erythrocyte mass results in the dilutional/physiological anaemia of pregnancy, most apparent at 30 to 34 weeks of gestation. Maintaining the correct iron balance is crucial for health. Our understanding of the molecular control of iron metabolism has increased dramatically over the past 5 years due to the discovery of hepcidin. Overexpression of the hepcidin gene resulted in mice that were severely iron deficient at birth [1]. Hepcidin is the predominant negative regulator of iron absorption in the small intestine, iron transport across the placenta, and iron release from macrophages [2]. High levels of hepcidin/prohepcidin have been found in patients with anaemia of chronic disease [3]. Based on these findings the aim of the study was to assess prohepcidin levels in pregnant women in relation to anaemia, inflammatory cytokines and iron status.
Material and methods
The studies were performed on 37 healthy pregnant women (third trimester), 34 anaemic pregnant women (third trimester), 20 healthy pregnant women (first trimester) and 30 healthy female volunteers. All patients were informed about the aim of the study and gave their consent. The study was approved by the Ethics Committee at the Doctors’ Council (Izba Lekarska) in Olsztyn. All the pregnancies were uneventful. There were no miscarriages in the pregnant females (studied at first trimester). In none of the pregnant females in advanced pregnancy was hypertension, gestational diabetes, hypotrophy or preterm labour observed. Laboratory tests were done at week 9 in pregnant females (first trimester) and at week 36 in pregnant females (third trimester). All the females were given folic acid. Pregnant females were also given iron supplements starting from confirmation of pregnancy (in the form of multivitamin supplements). Anaemia was diagnosed at the beginning of the third trimester and iron supplements in the form of oral iron were introduced. Since prohepcidin is affected by kidney function we included only females with normal kidney function [4]. Blood was taken without stasis. Prohepcidin was studied using commercially available kits from DRG Instruments GmbH (Marburg, Germany) and CRP was assayed by a high sensitivity method using commercially available kits from American Diagnostica (Greenwich, CT, USA). Soluble receptors of transferrin (sTfR) and interleukin-6 (IL-6) were studied using kits from R&D (Abington, UK). All tests were performed according to manufacturers’ instructions by the same person. The following parameters were measured by means of standard laboratory methods: haemoglobin, red blood cell count, total protein, albumin, cholesterol, triglycerides, and urea. Transferrin saturation (TSAT) was calculated as iron/total iron binding capacity (TIBC) ratio. Serum iron and other parameters (TIBC, TSAT, ferritin) were assessed after a one-week break in oral iron supplementation to avoid interpretation bias. Data were analyzed using Statistica 6.0 computer software. Normality of variable distribution was tested using Shapiro-Wilk W-test. If possible data were logarithmically transformed to achieve normal distribution. Data were reported as means ± SD. Analysis of variance (ANOVA) (with post-hoc Tukey test for unequal groups) or Kruskal-Wallis ANOVA (the difference between the means of two variables was calculated by Mann-Whitney U test) was used to compare differences between groups with P<0.05 considered statistically significant, when appropriate. Linear regression analysis employed Pearson or Spearman coefficients as appropriate. Multiple regression analysis was used to determine independent factors affecting dependent variables. Factors showing linear correlations with prohepcidin (P<0.01) were included in the multiple regression analysis.
Results
All the data are presented in Table I–III. In pregnant anaemic women in the third trimester prohepcidin, IL-6, hsCRP, sTfR, TIBC and TSAT were significantly higher than in non-anaemic pregnant women in the same trimester. Prohepcidin in every trimester was significantly higher than in non-pregnant healthy females. In anaemic pregnant females prohepcidin showed negative correlations with haemoglobin (r=–0.34, P<0.05), haematocrit (r=–0.39, P<0.05), and total protein (r=–0.34, P<0.05). In pregnant females in the first trimester prohepcidin was positively related to hsCRP (r=0.49, P<0.05). In all non-anaemic pregnant women (first and third trimester) prohepcidin correlated negatively with sTfR (r=–0.27, P<0.05) and positively with ferritin (r=0.26, P<0.05). In healthy volunteers prohepcidin was related positively to ferritin (r=0.37, P<0.05).
Discussion
In uncomplicated iron deficiency anaemia, both the anaemia per se and the absent iron stores provide a message to stop production of hepcidin, a protein produced in the liver which is felt to be a major regulator of iron balance. The absence of hepcidin enhances gastrointestinal iron absorption as well as the release of iron from stores in macrophages. Further loss of iron results in anaemia, which is initially normocytic with a normal absolute reticulocyte count. This stage of iron deficiency is common. It has been estimated that more than 20% of menstruant women in the United States have no iron reserves and are in this stage [5]. In our studies we found that prohepcidin was significantly higher in pregnant women than in healthy females, in contrast to the recent study of Roe et al. [6]. We studied a much larger population of pregnant females: 91 pregnant females, not only 13, as reported previously. In addition, we chose a control group of the same age, sex and kidney function to avoid potential bias. Roe et al. [6] compared hepcidin levels to those obtained in men over 40 years. The values obtained in our control group correspond to those reported by Kulaksiz et al. [7]. Moreover, in our study, prohepcidin was significantly higher in anaemic pregnant females than in non-anaemic in the third trimester. In the study of Laskowska-Klita et al. [8] prohepcidin was not affected by the duration of the pregnancy; however, they obtained values much higher than Roe et al. [6]. They did not provide reference values. Roe et al. [6] found that in 6 pregnant females iron supplementation did not affect prohepcidin levels. All of our patients were on multivitamin supplements including iron from the diagnosis of pregnancy, not from the 16th week. Measurement of serum ferritin is currently the accepted laboratory test for diagnosing iron deficiency, and a ferritin value of 12 µg/l is a highly specific indicator of iron deficiency [9]. Serum ferritin is useful in pregnant women who often have elevated serum transferrin in the absence of iron deficiency [10]. Other commonly used laboratory tests such as serum iron, total iron-binding capacity, mean corpuscular volume, and transferrin saturation provide little additional diagnostic value over ferritin. Measurement of serum iron and percent saturation of TIBC had significantly lower diagnostic accuracy. The accuracy of measurement of transferrin/TIBC for predicting the presence of iron deficiency is second only to the serum or plasma ferritin concentration. One problem is that pregnancy and oral contraceptives increase the plasma transferrin concentration [10]; as a result, the percent saturation may be low in such patients in the absence of iron deficiency. The soluble transferrin receptor, a truncated form of the membrane-associated transferrin receptor, has been reported to be a sensitive indicator of iron deficiency and is not an acute-phase reactant [11] Therefore, in our study we also assessed sTfR and its possible correlation with prohepcidin. In our study sTfR was related to prohepcidin in all non-anaemic pregnant females. In anaemic pregnant females prohepcidin correlated with haematocrit. In the recent study of Hsu et al. [12] the only predictor of prohepcidin in haemodialyzed patients was haematocrit, whereas in univariate analysis significant correlations between prohepcidin and IL-6, serum erythropoietin level and dose were observed. They did not discriminate between anaemic and non-anaemic patients. In all non-anaemic pregnant women prohepcidin was related to ferritin, as reported by Dallalio et al. [13] for anaemic patients undergoing bone marrow examinations. Kulaksiz et al. [7] reported elevated prohepcidin level in haemodialyzed patients. All of their 59 patients were treated 2-3 times a week with 3000 IU erythropoietin. However, they did not provide even basal clinical characteristics of studied patients, not even haemoglobin level. They only stated that patients with renal anaemia (a maximum haemoglobin concentration of 11 g/dl) had significantly lower hepcidin than patients with chronic renal insufficiency. No correlations between hepcidin, iron status, ferritin and transferrin saturation were observed in their study. In our previous study we found significantly higher hepcidin in non-anaemic HD patients treated with erythropoietin when compared to anaemic HD patients treated with erythropoietin [14]. In patients treated with erythropoietin in multiple regression analysis the only correlates of hepcidin were haemoglobin and erythropoietin dose. In our study pregnant females were given iron supplements, despite in some of them anaemia being diagnosed in the third trimester. It seems that anaemia in pregnancy is not only due to iron deficiency but also to subclinical inflammation as reflected by elevated IL-6 and CRP. According to the Centers for Disease Control and Prevention (CDC) pregnant women should begin taking low dose (30 mg/day) oral iron at the first prenatal visit as primary prevention of iron deficiency. Women should also be screened for iron deficiency at the first prenatal visit; the presence of anaemia warrants treatment with 60 to 120 mg of iron per day. Iron is best absorbed from an empty stomach in the reduced or ferrous form [15]. In conclusion, hepcidin is essentially a microbicidal peptide. Assuming that in certain conditions the body is particularly vulnerable (pregnancy, chronic kidney disease, inflammation), increased hepcidin synthesis in the liver will protect the organism against bacterial or microbial aggression or dissemination. However, the price to pay could be anaemia. Elevated hepcidin in pregnancy related to ferritin and sTfR may reflect an acute phase reaction, and either the cellular need for iron or the rate of erythropoiesis. In anaemia in pregnancy a cause-effect relationship between haematocrit and hepcidin might exist. A rise in prohepcidin in pregnancy may also be due to the fact that some proinflammatory cytokines play a fundamental role in inducing hepcidin gene expression, namely IL-6 [3].
References
1. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-8. 2. Ganz T. Hepcidin – a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 2005; 18: 171-82. 3. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-3. 4. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation and hemodialysis. Am J Hematol 2006; 81: 832-7. 5. Cook JD, Skikne BS, Lynch SR, Reusser ME. Estimates of iron deficiency in the US. population. Blood 1986; 68: 726-31. 6. Roe MA, Spinks C, Heath AL, et al. Serum prohepcidin concentration: no association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary hemochromatosis patients undergoing phlebotomy treatment, or pregnant women. Br J Nutr 2007; 97: 544-9. 7. Kulaksiz H, Gehrke SG, Janetzko A, et al. Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 2004; 53: 735-43. 8. Laskowska-Klita T, Chelchowska M, Ambroszkiewicz J, Swiatek E, Leibschang J. Serum pro-hepcidin and iron markers during uncomplicated pregnancy. Eur J Obstet Gynecol Reprod Biol 2007; 130: 273-4. 9. Suominen P, Möttönen T, Rajamäki A, Irjala K. Single values of serum transferrin receptor and transferrin receptor ferritin index can be used to detect true and functional iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum 2000; 43: 1016-20. 10. Bridges KR, Seligman PA. Disorders of iron metabolism. In: Blood: Principles and Practice of Hematology. Handin RI, Lux SE, Stossel TP (eds) 1995; chapter 49. 11. Bruns DE, Huth EJ, Magid E, Young DS. Toward a checklist for reporting of studies of diagnostic accuracy of medical tests. Clin Chem 2000; 46: 893-5. 12. Hsu SP, Chiang CK, Chien CT, Hung KY. Plasma prohepcidin positively correlates with hematocrit in chronic hemodialysis patients. Blood Purif 2006; 24: 311-6. 13. Dallalio G, Fleury T, Means T. Serum hepcidin in clinical specimens. Br J Haematol 2003; 122: 996-1000. 14. Małyszko J, Małyszko JS, Hryszko T, Pawlak K, Mysliwiec M. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients? Am J Nephrol 2005; 25: 586-90. 15. Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1998; 47(RR-3): 1-25.
Copyright: © 2008 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe